NCT01890343View on ClinicalTrials.gov

Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

December 31, 2012

Study Completion Date

April 30, 2013

Conditions
Alzheimer's DiseaseFrontotemporal Dementia
Interventions
DRUG

florbetapir 18F

Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.

DRUG

18F-FDG

FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.

Trial Locations (1)

M20 3LJ

Research Site, Manchester

Sponsors
All Listed Sponsors
lead

Avid Radiopharmaceuticals

INDUSTRY